To assess the long-term effects of mineralocorticoids on the regulation of the synthesis or release of kallikrein and prostaglandin E2 in the renal kallikrein-kininprostaglandin E system, we studied the effects of chronic infusion of aldosterone (50,ug/kg/day) on urinary excretion of total and active kallikrein, and prostaglandin E2 for 10 days in conscious rats on regular intakes of sodium and on sodium loading with 1% NaCI as a drinking water. Chronic infusion of aldosterone induced a prompt and transient decrease in the ratio of sodium to potassium and a sustained increase in urinary prostaglandin E2 excretion in rats on regular diets, whereas urinary total and active kallikrein excretion did not increase significantly until the 4th day of aldosterone infusion. In rats loaded with sodium, aldosterone did not induce any changes in urinary total and active kallikrein excretion, whereas it induced similar changes in the ratio of sodium to potassium and urinary prostaglandin E2 excretion to those in rats on regular diets. Thus, the present results suggest that aldosterone might stimulate the synthesis or release of renal prostaglandin E2 independent of sodium balance. Furthermore, it is also suggested that aldosterone might stimulate the synthesis or release of kallikrein, at least partly, via the same pathway as sodium loading does. mineralocorticoids ; inactive kallikrein ; trypsin-activated kallikrein ; renal prostaglandin E2 ; sodium balance It system 1977; is generally agreed that the renal kallikrein-kinin-prostaglandin (PG) E is involved in the regulation of electrolytes and water excretion (Dunn Levinsky 1979; Carretero and Scicli 1980) . It is well established that
YASUJIMA, M., ABE, K., TANNO, M., KOHZUKI, M., KANAZAWA, M., OMATA, K., KASAI, Y., SATO, M., TAKEUCHI, K., ITOH, S., IIIWATARI, M., SAITO, T., SASO, S. and YOSHINAGA, K. Long-Term Effects of Aldosterone on Kallikrein, Prostaglandin E2 and Sodium in Rats. Tohoku J. exp. Med., 1987, 152 (4), [351] [352] [353] [354] [355] [356] [357] [358] [359] [360] [361] [362] To assess the long-term effects of mineralocorticoids on the regulation of the synthesis or release of kallikrein and prostaglandin E2 in the renal kallikrein-kininprostaglandin E system, we studied the effects of chronic infusion of aldosterone (50,ug/kg/day) on urinary excretion of total and active kallikrein, and prostaglandin E2 for 10 days in conscious rats on regular intakes of sodium and on sodium loading with 1% NaCI as a drinking water. Chronic infusion of aldosterone induced a prompt and transient decrease in the ratio of sodium to potassium and a sustained increase in urinary prostaglandin E2 excretion in rats on regular diets, whereas urinary total and active kallikrein excretion did not increase significantly until the 4th day of aldosterone infusion. In rats loaded with sodium, aldosterone did not induce any changes in urinary total and active kallikrein excretion, whereas it induced similar changes in the ratio of sodium to potassium and urinary prostaglandin E2 excretion to those in rats on regular diets. Thus, the present results suggest that aldosterone might stimulate the synthesis or release of renal prostaglandin E2 independent of sodium balance. Furthermore, it is also suggested that aldosterone might stimulate the synthesis or release of kallikrein, at least partly, via the same pathway as sodium loading does. mineralocorticoids ; inactive kallikrein ; trypsin-activated kallikrein ; renal prostaglandin E2 ; sodium balance It system 1977;  is generally agreed that the renal kallikrein-kinin-prostaglandin (PG) E is involved in the regulation of electrolytes and water excretion (Dunn Levinsky 1979; Carretero and Scicli 1980) . It is well established that kallikrein in the urine arises within the kidney and its rate of excretion is a function of renal kallikrein synthesis (Nustad et al. 1975 ; Levinsky 1979; Carretero and Scicli 1980) although it cannot be excluded that glandular kallikrein from various origin is excreted in the urine. In addition, urinary PGEZ excretion is also regarded as an indicator of the synthesis of renal PGEZ (Frolich et al. 1975) . Several previous studies have demonstrated that mineralocorticoids could have a major regulatory influence on renal kallikrein and increase urinary kallikrein excretion (Levinsky 1979; Carretero and Scicli 1980) . That mineralocorticoids enhance the activity of the renal kallikrein-kinin system has been inferred from the finding of increased urinary kallikrein excretion in patients with primary aldosteronism and in patients and animals receiving sodium-retaining mineralocorticoids. Furthermore, it has also been reported that mineralocorticoids increase urinary PGEZ excretion (Nasjletti et al. 1978 ). Many efforts have been addressed to solve complex interactions between sodium intake, sodium excretion, prostaglandin and kallikrein excretion, and aldosterone (Nasjletti and Colina-Chourio 1975; Nasjletti and Malik 1981) . However, the physiological relevance of mineralocorticoids to the regulation of renal kallikrein-kinin-PGE system has remained to be determined in detail. In addition, the effect of mineralocorticoids on the excretion of inactive kallikrein has not been studied whereas it has been recently reported that part of kallikrein is present in an inactive form which can be activated by trypsin in the kidney in rats (Yamada and Erdos 1982; Nishimura et al. 1983; Van Leeuwen et al. 1984 ) as well as in rabbits (Omata et al. 1982 ) and human (Corthorn et al. 1979 ). It would therefore be needed to examine the long-term effects of moderate dose of aldosterone that can produce plasma levels similar to those observed in many clinical situations, on renal kallikrein-kinin-PGE system.
In the present study, we assessed the effects of chronic aldosterone administration on urinary excretion of total, active and inactive kallikrein, and PGEZ in conscious rats.
MATERIAL AND METHODS
Experiments were performed on 28 male Sprague-Dawley rats weighing 150 to 250 g. All rats were maintained in a humidity-and temperature-controlled room, each rat being housed in a metabolic cage during the study. The metabolic cage was deviced to prevent feces-urine contact (Model Metabolism Cage ST type, Sugiyamagen Corporation, Tokyo). The rats were fed on a regular diet (Oriental CMF, 0.24% of sodium, 0.69% of potassium, Oriental Yeast, Tokyo) and had free access to tap water.
Studies were performed after a 7 day period of acclimatization to the housing, feeding and drinking conditions. Fourteen rats were sodium-loaded and 14 were not. After subsequent 7 day period, each animal was anesthetized with ether, and an Alzet osmotic minipump (Model 2002, Alza Corporation, Palo Alto, CA, USA), filled with aldosterone solution or vehicle, was placed in the abdominal cavity through a middle incision, which was then closed with autoclips. D-Aldosterone (Wako Pure Chemical Industries Ltd., Osaka) was dissolved in polyethylene glycol. Seven sodium-loaded and 7 unloaded rats were infused with aldosterone at a rate of 50 jig/kg /day for up to 10 days. Another group of rats, 7 sodium-loaded and 7 unloaded, received only polyethylene glycol. Assuming that aldosterone did not degrade during the study, the pumps dispensed fluid at the specified rate of approximately 0.5 ,u1/hr. The infusion dose was set to induce and maintain a distinct elevation of circulating levels of aldosterone, and not to affect the blood pressure, essentially according to the schedule deviced by Garwitz and Jones (1982) . Daily systolic blood pressure was recorded in conscious rats by an indirect tail cuff method (Pfeffer et al. 1971 ). The daily fluid intake, urine volume, urinary sodium excretion, urinary total, active and inactive kallikrein excretion, and urinary PGE2 excretion were determined. Urine was collected into vessels chilled at 4°C and kept at -20°C until the assay. Blood for the measurements of plasma renin activity and plasma aldosterone concentration was obtained by decapitation at the termination of each experiment.
Active kallikrein in urine samples was measured by its kininogenase activity (kinin releasing capability) using the method of Abe et al. (1979) . Briefly, urine samples were incubated with purified bovine serum low molecular weight kininogen as substrate, generously supplied by Dr. H. Kato (Fukuoka), in the presence of 3 mM 1-10 phenanthroline (Wako Pure Chemical Industries Ltd.), 30 mM disodium ethylene-diamine tetraacetic acid (EDTA) (Wako Pure Chemical Industries Ltd.), and 0.1% neomycin (Takeda Pharmaceutical Company, Osaka). The samples were incubated at 37°C for 20 min, and the reaction was stopped by heating in a boiling water bath for 5 min. Then the samples were diluted, and the generated kinins were radioimmunologically measured by a modification of the method of Carretero et al. (1976) . Kallikrein activity is expressed as an amount of kinin per ml of urine generated by the incubation of urine samples with bovine serum low molecular weight kininogen for 20 min. Total kallikrein was determined by measuring the kininogenase activity in urine samples after inactive kallikrein had been activated with trypsin, and inactive kallikrein was calculated as the difference between total kallikrein (both active and inactive kallikrein) and active kallikrein (Yasujima et al. 1986 ). In order to activate the inactive kallikrein, urine samples were incubated with trypsin, and the reaction was stopped by soy bean trypsin inhibitor (SBTI) (Wako Pure Chemical Industries Ltd.). Kininogenase activity was then measured as described above. To determine the optimal amount of trypsin to activate urinary inactive kallikrein in the preliminary experiments, the pooled rat urine (10 ,u l) from 10 normal rats was incubated with trypsin at doses of 0.1, 0.5, 2, 5 and 10 p g for 30 min at 37°C. The reaction was stopped by adding 100,ug of SBTI. Maximum activation of urinary inactive kallikrein with trypsin was observed at the concentration of 0.2,ug/,ul. The dose of SBTI employed, inhibited completely the kininogenase activity of trypsin used in the present experiments. Furthermore, we confirmed that the doses of trypsin and SBTI employed in the present experiment did not affect the radioimmunoassay of kinins. Pooled urine collected from 10 normal rats was assayed to test the reproducibility. Inter-assay coefficient of variation for active kallikrein was 10.4% (8 estimations), and the coefficient for total kallikrein was 13.4% (8 estimations). Intea-assay coefficient of variation for active kallikrein was 9.6% in 8 estimations, and the coefficient for total kallikrein was 12.4% in 8 estimations. Urinary PGE2 was measured by the modified method described previously (Abe et al. 1977 (Abe et al. , 1978 . Urine was acidfied to pH 3 with hydrochloric acid and extracted with 5 volumes of ethyl acetate. The dried organic extract was then chromatographed on a silicic acid column for separation of PGE2, which was then eluted by a mixture of benzene and ethyl acetate (60: 40) according to Jaffe's method. The PGE2 was dried and measured radioimmunologically using PGE2 antiserum (Pasteur Institute, Paris, France). The overall recovery of PGE2 was 60%. Inter-assay coefficient of variation for PGE2 was 9.2% (6 estimations), and the intra-assay coefficient of variation was 7.0% (9 estimations). Urinary concentration of sodium and potassium were measured with a flame photometer. Plasma renin activity was radioimmunologically determined by a modification of Haber's method (Abe et al. 1971 ). Plasma aldosterone concentration was radioimmunologically measured with a commercial kit (Dainabot Phar-maceutical Company, Tokyo).
All results were expressed as mean+s.E. Statistical analysis of the data between groups was performed by two-way analysis of variance for repeated measurements. Statistically significant differences on each day were isolated by the unpaired t-test between groups. The significance of the changes in some parameters between groups was also evaluated using the unpaired 1-test.
RESULTS
The effects of intraperitoneal infusion of aldosterone on body weight, systolic blood pressure, urine volume and urinary sodium and potassium excretion in rats on regular diets are show in Table 1 and on sodium loading with 1% NaCI in Table 2 . In sodium-unloaded rats, intraperitoneal infusion of aldosterone up to 10 days did not induce any changes in body weight, systolic blood pressure, urine volume and urinary sodium and potassium excretion when compared with values in vehicle-infused rats (Table 1) , whereas the plasma aldosterone concentration TABLE 1. Chronic effects of aldosterone (ALDO) infusion in rats on regular diets was increased from 19.2+ 1.0 to 30.1+5.2 ng/100 ml (p <0.05) and the plasma renin activity was reduced from 5.5+0.3 to 1.8+0.4 ng/ml/hr (p <0.01). Body weight gain in rats receiving aldosterone for 10 days (51.9+3.3 g) was greater than in vehicle-infused controls (38.7+4.6 g) (p <0.05). In sodium-loaded rats, the systolic blood pressure of the aldosterone group began to rise significantly on the 4th day and remained high up to the end of experiment, whereas that of the vehicle group did not change (Table 2) . Concomitantly, intraperitoneal infusion of aldosterone induced a significant increase in urinary sodium excretion of the 4th day in sodium-loaded rats, which sustained for up to the end of experiment. Urinary potassium excretion is transiently increased during chronic infusion of TABLE 2. Chronic effects of aldosterone (ALDO) infusion in rats on sodium loading with 1 % NaCI aldosterone in sodium loaded rats, whereas body weight and urine volume did not change ( Table 2 ). The time course of changes in the ratio of sodium to potassium induced by aldosterone infusion is depicted in Fig. 1 . As can be seen, the effect of aldosterone on sodium and potassium excretion was evident initially but only transient in sodium loaded and unloaded rats. With infusion of aldosterone, the plasma aldosterone concentration was increased from 12.4± 1.0 to 20.7± 2.0 ng/ 100 ml (p <0.01) in sodium-loaded rats whereas the plasma renin activity was reduced from 3.1+0.3 to 0.7+0.2 ng/ml/hr (p <0.01). Body weight gain in rats receiving aldosterone for 10 days was not different from that in vehicle-infused rats on sodium loading with 1% NaCI. Fig. 2 shows the urinary excretion of total, active and inactive kallikrein in aldosterone-or vehicle-infused rats on regular diets. Compared with values in vehicle-infused rats, urinary total, active, and inactive kallikrein excretion increased significantly in rats infused with aldosterone, although the ratio of active to total kallikrein was not changed. A significant increase in urinary kallikrein was seen on the 4th day of implantation of minipumps and the maximal effect was observed on the 8th and 10th day, although the effect of aldosterone on electrolytes was evident on the 2nd day of aldosterone infusion. However, as shown in Fig. 3 , in rats on sodium loading with 1% NaCI intraperitoneal infusion of aldosterone at a rate of 50 ,u g/kg/day did not induce any changes in the urinary excretion of total, active and inactive kallikrein compared with values in vehicle infused rats. In both sodium conditions, intraperitoneal infusion of aldosterone induced a significant and sustained increase in urinary PGEZ excretion (Fig. 4) . Aldosterone infusion induced a 122% maximal increase in rats on regular diets and a 118% maximal increase in rats on sodium loading with 1% NaCI. increase in urinary active kallikrein excretion on different sodium diets (FejesToth and Naray-Fejes-loth 1984). In rats on ordinary intakes of sodium, exogenous aldosterone induced significant increases in urinary excretion of total, active and inactive kallikrein, but did not affect the ratio of active to total kallikrein.
The concomitant changes in active and inactive enzyme values suggest that increased synthesis might have been responsible for the increase in active kallikrein excretion.
In our previous study (Yasujima et al. 1986 ), we reported that chronic sodium loading with 1% NaCI for 6 days increased continuously urinary total, active and inactive kallikrein excretion and chronic infusion of angiotensin II also increased the urinary kallikrein.
But the angiotensin II infusion did not induce any changes in urinary kallikrein excretion in sodium-loaded rats, suggesting that angiotensin II might stimulate the synthesis of kallikrein, at least, via the same mechanism as sodium loading does. In the present study, the failure of the increase in urinary excretion of total, active and inactive kallikrein after the chronic infusion of aldosterone was observed in sodium-loaded rats, which suggest again that aldosterone might stimulate the synthesis of kallikrein, at least, via the same mechanism as sodium loading does. Another possible explanation for the failure of aldosterone to increase urinary excretion of total, active and inactive kallikrein in sodium-loaded rats might be that kallikrein excretion had reached its upper limit after sodium loading for 7 days, since the baseline values for urinary kallikrein excretion in the rats on sodium loading are significantly greater than those obtained after aldosterone infusion in the rats on regular diets. However, it was not possible to determine the upper limit of the urinary kallikrein excretion response to aldosterone or sodium loading in the present study, since no assessment was made of the response of urinary kallikrein to graded doses of aldosterone or dietary sodium. In addition, the elevated blood pressure induced by sodium loading might be affect the urinary kallikrein excretion response to aldosterone. However the exact mechanism also remains to be elucidated.
It is also interesting to note that until the 4th day of the infusion aldosterone did not induce any increase in urinary kallikrein excretion whereas aldosterone had already induced a change in the ratio of urinary sodium to potassium on the 2nd day of treatment. The animals on the ordinary intakes of sodium escaped from the effect of aldosterone by the 6th day of treatment, associated with the progressive increase in urinary kallikrein excretion, suggesting a involvement of renal kallikrein in the escape phenomenon as suggested previously (Marin-Grez et al. 1973; Zipser et al. 1978) . In contrast, no significant changes were observed in urinary kallikrein excretion during the administration of aldosterone in sodiumloaded rats, whereas the escape phenomenon from the effect of aldosterone occurred more promptly in sodium-loaded rats than in rats on ordinary intakes of sodium, associated with the increase in systolic blood pressure. These results may represent that renal kallikrein-kinin system can counteract the sodium-retaining effect of aldosterone to some extents. In addition, the elevation of blood pressure could occur when the effect of aldosterone overcome the activity of renal kallikrein-kinin system, which may in turn contribute to the natriuresis. However, the exact mechanism underlying the escape phenomenon from the effect of aldosterone remains to be determined.
Several previous studies have examined how mineralocorticoids and sodium balance regulate urinary PGE2 excretion, obtaining the results which suggested that mineralocorticoids may augment the activity of renal kallikrein kinin system and promote the renal production of kinins, which in turn stimulate the synthesis or release of PGE2 (Nasjletti et al. 1978 ; Durr et al. 1982) . However, in the present study the dissociation of responses of urinary PGE2 excretion to exogenous aldosterone from those of urinary kallikrein excretion in sodium-loaded rats did not seem to support the hypothesis that mineralocorticoids stimulate release of PGE2 via the enhanced production of renal kinins. Furthermore, the results of the present experiments that animals on different sodium conditions responded with similar enhancement of urinary PGE2 excretion to exogenous aldosterone, seem to argue against the concept that the effect of aldosterone is mediated by volume expansion known to be a maneuver to suppress vasopression which stimulates the synthesis and release of renal PGs (Zusman and Keiser 1977; Fejes-Toth and Mann 1983 ; Yasujima et al. 1984) . It would be also reasonable to assume that the effect of aldosterone on PGE2 is not secondary to sodium retention, since the response of urinary PGE2 excretion to sodium retention induced by chronic infusion of aldosterone might be independent of the sodium balance that existed before aldosterone administration.
Thus increased urinary PGE2 excretion induced by aldosterone administration may not be related directly to any consistent changes in electrolytes and hormones, which seems to argue against the concept that sodium retention, potassium depletion, and increased urine volume and urinary kallikrein excretion induced by sodium-retaining steroids contribute to increased urinary PGE2 excretion. Further studies are necessary to assess the effects of aldosterone on urinary PGE2 excretion, since it is not ruled out that unknown factors including atrial natriuretic factors identified recently (Flynn et al. 1983; Misono et al. 1984) , which are released by the changes in the volume of body fluid, could modify renal PGE2 system. Additionally, it is worth mentioning that a sustained increase in urinary PGE2 excretion occurring in both sodium conditions might be preceded by the escape phenomenon from the sodium-retaining effects of aldosterone. Taken together with the results on urinary kallikrein excretion and systolic blood pressure, it is suggested that renal kallikrein-kinin-PGE2 system can contribute to the escape phenomenon from the sodium-retaining effects of aldosterone. The gradual elevation of systolic blood pressure induced by chronic infusion of aldosterone occurred in sodium-loaded rats whereas urinary PGE2 excretion increased promptly and continuously, suggesting again that the effect of aldosterone might overcome the activity of renal PGE2 system. 
